Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | PER2 | O15055 | 1/20 | 0.41 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.41 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29909776 | 1.00 | DYRK1A (0.44) | DYRK1APER2CRY1CRY2KMT2A | |
| SCHEMBL23576748 | 0.94 | CYP1A2 (0.44) | DYRK1AKMT2AUSP2CYP1A2CYP3A4 | |
| SCHEMBL29909727 | 0.94 | CYP1A2 (0.44) | DYRK1AKMT2AUSP2CYP1A2CYP3A4 | |
| SCHEMBL29909632 | 0.88 | EGFR (0.40) | USP2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL23577808 | 0.88 | EGFR (0.40) | USP2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL23577069 | 0.87 | EGFR (0.52) | SMN1; SMN2EGFRPDGFRBKDR | |
| SCHEMBL29909686 | 0.87 | EGFR (0.52) | SMN1; SMN2EGFRPDGFRBKDR | |
| SCHEMBL23577319 | 0.87 | SMN1; SMN2 (0.35) | DYRK1ASMN1; SMN2 | |
| SCHEMBL29909117 | 0.87 | SMN1; SMN2 (0.35) | DYRK1ASMN1; SMN2 | |
| SCHEMBL23577048 | 0.85 | CSF1R (0.49) | EGFRPDGFRBKDRCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4445902-A2 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2024-10-16 | — | — | EP | disclosed |
| EP-4081305-B1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES INC (JP) | 2024-09-18 | — | — | EP | disclosed |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-06-06 | — | — | US | disclosed |
| US-11845723-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| EP-4081305-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | DYRK1A 1410/4885PER2 3692/4885CRY1 4814/4885 |
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | DYRK1A 1410/4885PER2 3692/4885CRY1 4814/4885 |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | DYRK1A 1410/4885PER2 3692/4885CRY1 4814/4885 |
| US-11845723-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | DYRK1A 1410/4885PER2 3692/4885CRY1 4814/4885 |
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | DYRK1A 1410/4885PER2 3692/4885CRY1 4814/4885 |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | DYRK1A 1410/4885PER2 3692/4885CRY1 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.